Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Expression data from BRAF-mutant melanoma cell lines

ABSTRACT: Melanoma cell lines were assessed for differences in gene expression patterns between the lines sensitive and resistant to BRAF and MEK inhibitor drugs. 22 BRAF-mutant melanoma cell lines were assessed for response to BRAF and MEK inhibitors in a 3 day drug treatment dose response assay. Based on the IC50, 18 lines were found to be responsive to BRAF or MEK inhibition and 4 were resistant. Normalised gene expression data generated from experimental replicate affymetrix arrays was assessed to identify differential patterns of inherent gene expression between the cell lines grouped as drug-responsive or drug-resistant. This were used to idenify specific candidate genes and pathways associated with inherent BRAF/MEK inhibitor drug resistance in melanoma cells.

ORGANISM(S): Homo sapiens

SUBMITTER: Petranel Ferrao 

PROVIDER: E-GEOD-45558 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Most patients with BRAF-mutant metastatic melanoma display remarkable but incomplete and short-lived responses to inhibitors of the BRAF kinase or the mitogen-activated protein kinase kinase (MEK), collectively BRAF/MEK inhibitors. We found that inherent resistance to these agents in BRAF(V600)-mutant melanoma cell lines was associated with high abundance of c-JUN and characteristics of a mesenchymal-like phenotype. Early drug adaptation in drug-sensitive cell lines grown in culture or as xenogr  ...[more]

Similar Datasets

Unknown Expression data from BRAF-mutant melanoma cell lines
2015-08-26 | GSE45558 | GEO
Transcriptomics Human BRAF-V600E melanoma cell lines drug sensitive vs drug resistant
2014-04-21 | E-GEOD-49430 | biostudies-arrayexpress
Unknown RNA Seq data: A375, A375R, A375DR vorinostat treated, and biopy samples from patients pre- and post- treated with Vorinostat
2018-04-18 | GSE110948 | GEO
Unknown DNA Seq data: biopy samples from patients pre- and post- treated with Vorinostat
2018-04-18 | GSE111140 | GEO
Proteomics HDAC8 regulates escape from BRAF inhibitor therapy in Melanoma: Phosphotyrosine Profiling
2020-07-07 | PXD012812 | Pride
Proteomics HDAC8 regulates escape from BRAF inhibitor therapy in Melanoma: IMAC Phosphoproteomics
2020-07-07 | PXD012813 | Pride
Unknown Suppression of heparan sulfation resensitizes YAP1-driven BRAF mutant melanoma to MAPK pathway inhibitors
2022-08-15 | GSE193775 | GEO
Transcriptomics Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma: Implications for treatment beyond disease progression
2013-06-30 | E-GEOD-44753 | biostudies-arrayexpress
Transcriptomics Impact of BRAF kinase inhibitors on miRNomes and transcriptomes of melanoma cells (gene expression dataset)
2017-03-06 | E-MTAB-5511 | biostudies-arrayexpress
Transcriptomics Impact of BRAF kinase inhibitors on miRNomes and transcriptomes of melanoma cells (miRNA dataset)
2017-03-06 | E-MTAB-5510 | biostudies-arrayexpress